肺癌患者血清中解整合素-金属蛋白酶的表达及意义

Expression and Clinical Significance of ADAM10 in Serum of Lung Cancer Patients

目的:探讨解整合素-金属蛋白酶(ADAM10)在肺癌患者血清中的表达及临床意义。方法:应用ELISA方法检测58例肺癌患者、34例良性肺病患者及31例正常健康者血清中ADAM10蛋白表达水平,用放射免疫分析法检测上述研究对象血清中癌胚抗原(CEA)的蛋白表达水平。结果:ADAM10和CEA血清水平及阳性率,肺癌组为(255.6±26.5pg/mL,62.1%;16.5±6.7ng/mL,51.7%),均高于肺良性疾病组(124.8±12.5pg/mL,11.8%;8.2±1.3ng/mL,8.8%)和正常对照组(102.7±10.3pg/mL,6.5%;7.9±0.9ng/mL,3.2%),P<0.01;ADAM10在肺癌伴淋巴结转移患者血清中的表达水平的平均值(338.5±26.9pg/mL)和阳性率(72.2%)高于不伴淋巴结转移肺癌患者(P<0.01);ADAM10在肺腺癌患者血清中表达水平的平均值(308.5±26.9)和阳性率(88.2%)高于肺鳞癌及其他类型肺癌患者(P<0.01);CEA在肺腺癌患者血清中表达水平(18.7±7.4ng/mL)及阳性率(64.7%)也高于肺鳞癌和其他类型肺癌患者(P<0.05)。结论:ADAM10与肺癌的发生和转移有关;ADAM10和CEA均与肺腺癌易于发生全身转移有关。

Objective： To explore the expression and clinical significance of ADAMIO in serum of lung cancer patients. Methods： In 58 cases of lung cancer, 34 of lung benign lesions and 31 healthy individuals, we assessed the the serum protein level of ADAM10 with ELISA, and that of CEA with radioimmunoassay. Results： The serum levels of ADAM 10 and CEA were 255.6±26.5 pg/mL and 16.5 ±6.7 ng/mL, detectable in 62.1% and 51.7% of patients with lung cancer. These figures were higher than those for lung benign lesions （124.8±12.5 pg/mL in 11.8% and 8.2±1.3 ng/mL in 8.8%） and normal controls （102.7± 10.3 pg/mL in 6.5% and 7.9±0.9 ng/mL in 3.2%）（P〈0.01 ）. Among patients with lung cancer, the serum level and positive rate of ADAM10 were significantly higher in those with lymph node metastasis （338.5±26.9 pg/mL, 72.2%） compared with those free of lymph node lesions （P〈0.01）, and in adenocarcinoma （308.5± 26.9 pg/mL, 88.2%） compared with squamous cell carcinoma and other pathologic types （P〈0.01）, as were the data for CEA in adenocarcinoma （18.7 ± 7.4 ng/mL, 64.7%） compared with other pathologic types （P〈0.05）. Conclusion： ADAM10 appears closely related to occurrence and metastasis of lung cancer. The high level of ADAM10 and CEA expressions in patients with lung adenocarcinoma may be attributed to the greater chance of systemic metastasis seen in this condition.